# Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

> **NCT02063685** · PHASE3 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 807 (actual)

## Conditions studied

- Follicular Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** R-CHOP or R-bendamustine
- **DRUG:** Observation
- **DRUG:** Maintenance weekly x4
- **DRUG:** Ibritumomab Tiuxetan + Maintenance
- **DRUG:** Standard Maintenance

## Key facts

- **NCT ID:** NCT02063685
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 807 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063685, "Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02063685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*